샘플 요청 목록

 카트 문의
시장보고서
상품코드
1774875

세계의 제네릭 의약품 수탁제조 시장

Generic Pharmaceuticals Contract Manufacturing
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 494 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 제네릭 의약품 수탁제조 시장은 2030년까지 927억 달러에 이를 전망

2024년에 732억 달러로 추정되는 제네릭 의약품 수탁제조 세계 시장은 2024-2030년간 CAGR 4.0%로 성장하여 2030년에는 927억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 API는 CAGR3.1%를 나타내고, 분석 기간 종료시에는 530억 달러에 이를 것으로 예측됩니다. 의약품 부문의 성장률은 분석 기간중 CAGR 5.3%로 추정됩니다.

미국 시장은 약 199억 달러, 중국은 CAGR 7.2%로 성장 예측

미국의 제네릭 의약품 수탁제조 시장은 2024년에 199억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 187억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.2%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.7%와 3.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.3%로 성장할 전망입니다.

세계의 제네릭 의약품 수탁제조 시장 - 주요 동향과 촉진요인 정리

제네릭 의약품에 수탁제조이 필수적인 이유는?

제네릭 의약품 수탁제조 시장은 제약사들이 의약품 제조를 전문 수탁제조기관(CMO)에 위탁하는 경향이 강화됨에 따라 크게 성장하고 있습니다. 비용 효율적이고 고품질의 제네릭 의약품에 대한 수요가 증가함에 따라 제약사들은 CMO를 활용하여 생산 효율화, 규제 준수, 시장 진입을 가속화하기 위해 CMO를 활용하고 있습니다. CMO는 제제 개발, 원료의약품(API) 제조, 포장, 물류 등 엔드투엔드 서비스를 제공함으로써 제약 브랜드는 연구, 마케팅, 상품화에 집중할 수 있습니다.

블록버스터 의약품의 특허가 만료됨에 따라 제네릭 의약품에 대한 수요가 증가함에 따라 기업들은 효율적이고 확장 가능한 제조 솔루션을 찾고 있으며, CMO는 FDA, EMA, WHO의 우수의약품 제조 및 품질관리기준(GMP) 및 규제 표준을 준수하면서 대규모 생산에 대한 높은 수준의 역량을 제공합니다. 고도의 생산 능력을 제공합니다. 또한, 방출제어 정제, 주사제, 바이오시밀러 등 의약품의 제형이 복잡해짐에 따라 제약사들은 복잡한 제형에 대한 최첨단 설비와 전문성을 갖춘 위탁 생산업체와 협력하고 있습니다. 규제 당국의 감시가 강화되고 제네릭 의약품 시장의 경쟁이 치열해짐에 따라, 수탁제조은 전 세계 제약사들에게 필수적인 전략이 되고 있습니다.

제네릭 의약품 수탁제조 수요를 견인하는 요인은 무엇인가?

제네릭 의약품 수탁제조에 대한 수요는 비용 효율성, 규제에 대한 전문성, 세계 시장 확대에 따라 크게 좌우됩니다. 정부와 의료 서비스 제공업체들이 의료비 절감을 위해 저렴한 대체 의약품을 찾는 가운데, 제네릭 의약품의 대량 생산에 대한 수요가 급증하고 있습니다. 위탁 생산 업체는 규모의 경제를 활용하고, 공급망을 최적화하고, 제조 인프라에 대한 자본 지출을 줄임으로써 제약사의 제조 비용 절감을 돕고 있습니다.

또한, 엄격한 규제 요건으로 인해 자체 제조는 점점 더 복잡하고 자원 집약적이며, CMO는 규제 준수를 전문으로 하며 제네릭 의약품이 국제 품질 및 안전 표준을 충족하도록 보장합니다. 이는 미국, 유럽, 일본 등 규제가 엄격한 시장에 진출하는 기업에게 특히 중요합니다. 또한 심혈관 질환, 당뇨병, 암과 같은 만성 질환 증가는 제네릭 의약품에 대한 수요를 증가시키고 있으며, 제약사들은 세계 수요 증가에 대응하기 위해 제조 아웃소싱을 추진하고 있습니다. 제약 산업이 계속 진화하는 가운데, 수탁제조은 제네릭 의약품 제조의 효율성, 확장성, 경제성을 높이는 데 중요한 역할을 할 것으로 예측됩니다.

제네릭 의약품 수탁제조의 최신 기술 발전은?

의약품 수탁제조의 기술 발전은 효율성, 품질, 생산 능력을 크게 향상시켰습니다. 연속 생산 기술의 채택은 실시간 모니터링이 가능하고, 낭비를 줄이고, 배치 간 편차를 최소화함으로써 의약품 제조에 혁명을 일으켰습니다. 이러한 혁신은 생산성을 향상시키고 제네릭 의약품 시장 출시 시간을 단축하여 신속하고 비용 효율적인 의약품 제조에 대한 수요를 증가시켰습니다.

자동화 및 인공지능(AI)은 품질 관리, 예지보전, 공급망 관리를 최적화함으로써 수탁제조에 변화를 가져왔으며, AI 기반 분석을 통해 제조업체는 잠재적 결함을 감지하고, 생산 일정을 최적화하며, 보다 높은 정확도로 규제 준수를 보장할 수 있게 되었습니다. 수 있습니다. 또한, 나노캡슐화 및 리포좀 약물 전달과 같은 첨단 제형 기술의 통합을 통해 CMO는 장시간 지속형 주사제 및 바이오시밀러를 포함한 복잡한 제네릭 의약품을 개발할 수 있게 되었습니다. 의약품 수탁제조이 디지털화와 혁신을 계속 수용함에 따라, 업계는 효율성을 높이고 더 높은 품질의 의약품을 생산할 수 있는 태세를 갖추고 있습니다.

제네릭 의약품 수탁제조 시장의 성장을 가속하는 요인은 무엇인가?

제네릭 의약품 수탁제조 시장의 성장은 저렴한 의약품에 대한 수요 증가, 복잡한 규제, 제조 기술 발전 등 여러 요인에 의해 주도되고 있습니다. 전 세계 정부와 의료 서비스 제공업체들은 비용 효율적인 대체 의약품에 대한 관심이 높아지면서 제네릭 의약품의 생산이 급증하고 있습니다. 브랜드 의약품의 특허가 만료되는 것도 시장을 더욱 활성화시키고, 위탁 생산업체가 대규모 생산을 지원할 수 있는 기회를 창출하고 있습니다.

또한, 의약품 공급망의 세계화와 GMP 준수 시설의 필요성으로 인해 제약사들은 규제 준수 및 품질 보증을 전문으로 하는 CMO와의 제휴를 추진하고 있습니다. 바이오시밀러 및 특수 제네릭 의약품으로의 전환은 복잡한 제형에 대한 수탁제조 전문 지식에 대한 수요를 더욱 증가시키고 있습니다. 또한 디지털 기술, 자동화, AI 기반 제조 공정의 도입으로 생산 효율성이 향상되어 운영 비용을 절감하고 의약품의 품질을 개선할 수 있게 되었습니다. 제약 산업이 계속 진화하는 가운데, 수탁제조은 제네릭 제약사에게 확장성, 비용 효율성, 세계 시장 확대의 핵심 요소로 자리매김할 것입니다.

부문

제품(API, 의약품);의약품(브랜드 제네릭, 비브랜드 제네릭);투여 경로(경구, 비경구, 국소, 기타 투여 경로);용도(종양학 용도, 면역학 용도, 항당뇨병 용도, 신경학 용도, 항응고제용도, 심장혈관 용도, 호흡기 용도, 통증 용도, HIV 항바이러스제 용도, 기타 용도)

조사 대상 기업 예

  • AbbVie Inc.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim
  • Catalent Pharma Solutions
  • CordenPharma
  • Dr. Reddy's Laboratories
  • Fareva
  • Hovione
  • Jubilant Life Sciences Limited
  • Laurus Labs Limited
  • Lonza Group
  • Lupin Limited
  • Piramal Pharma Solutions
  • Recipharm AB
  • Samsung Biologics
  • Siegfried Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific
  • WuXi AppTec

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.31

Global Generic Pharmaceuticals Contract Manufacturing Market to Reach US$92.7 Billion by 2030

The global market for Generic Pharmaceuticals Contract Manufacturing estimated at US$73.2 Billion in the year 2024, is expected to reach US$92.7 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. API, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$53.0 Billion by the end of the analysis period. Growth in the Drug Product segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.9 Billion While China is Forecast to Grow at 7.2% CAGR

The Generic Pharmaceuticals Contract Manufacturing market in the U.S. is estimated at US$19.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$18.7 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Generic Pharmaceuticals Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Contract Manufacturing Becoming Essential for Generic Pharmaceuticals?

The generic pharmaceuticals contract manufacturing market has witnessed significant expansion as pharmaceutical companies increasingly outsource drug production to specialized contract manufacturing organizations (CMOs). With the growing demand for cost-effective and high-quality generic medications, pharmaceutical firms are leveraging CMOs to streamline production, ensure regulatory compliance, and accelerate market entry. Contract manufacturers provide end-to-end services, including formulation development, active pharmaceutical ingredient (API) production, packaging, and logistics, enabling pharmaceutical brands to focus on research, marketing, and commercialization.

The rising patent expirations of blockbuster drugs have fueled the demand for generic pharmaceuticals, driving companies to seek efficient and scalable manufacturing solutions. CMOs offer advanced capabilities in large-scale production while ensuring compliance with Good Manufacturing Practices (GMP) and regulatory standards set by the FDA, EMA, and WHO. Additionally, the increasing complexity of drug formulations, including controlled-release tablets, injectables, and biosimilars, has prompted pharmaceutical firms to partner with contract manufacturers equipped with state-of-the-art facilities and expertise in complex dosage forms. As regulatory scrutiny intensifies and competition in the generic drug market rises, contract manufacturing is becoming an indispensable strategy for pharmaceutical companies worldwide.

Which Factors Are Driving the Demand for Generic Drug Contract Manufacturing?

The demand for generic pharmaceuticals contract manufacturing is largely driven by cost efficiency, regulatory expertise, and global market expansion. With governments and healthcare providers pushing for affordable drug alternatives to reduce healthcare costs, the need for high-volume generic drug production has surged. Contract manufacturers help pharmaceutical companies lower production costs by leveraging economies of scale, optimizing supply chains, and reducing capital expenditures on manufacturing infrastructure.

Additionally, stringent regulatory requirements have made in-house manufacturing increasingly complex and resource-intensive. CMOs specialize in regulatory compliance, ensuring that generic drugs meet international quality and safety standards. This is particularly crucial for companies entering highly regulated markets such as the United States, Europe, and Japan. The increasing prevalence of chronic diseases, including cardiovascular disorders, diabetes, and cancer, has also fueled demand for generic medications, prompting pharmaceutical companies to outsource production to meet rising global needs. As the pharmaceutical industry continues to evolve, contract manufacturing is expected to play a vital role in enhancing efficiency, scalability, and affordability in generic drug production.

What Are the Latest Technological Advancements in Generic Pharmaceuticals Contract Manufacturing?

Technological advancements in pharmaceutical contract manufacturing have significantly improved efficiency, quality, and production capabilities. The adoption of continuous manufacturing technology has revolutionized drug production by enabling real-time monitoring, reducing waste, and minimizing batch-to-batch variability. This innovation enhances productivity and accelerates time-to-market for generic drugs, addressing the growing demand for rapid and cost-effective medication production.

Automation and artificial intelligence (AI) have also transformed contract manufacturing by optimizing quality control, predictive maintenance, and supply chain management. AI-driven analytics help manufacturers detect potential defects, optimize production schedules, and ensure regulatory compliance with greater accuracy. Additionally, the integration of advanced formulation techniques, such as nanoencapsulation and liposomal drug delivery, has enabled CMOs to develop complex generics, including long-acting injectables and biosimilars. As pharmaceutical contract manufacturing continues to embrace digitalization and innovation, the industry is poised for enhanced efficiency and higher-quality drug production.

What Factors Are Fueling the Growth of the Generic Pharmaceuticals Contract Manufacturing Market?

The growth in the generic pharmaceuticals contract manufacturing market is driven by several factors, including the increasing demand for affordable medications, regulatory complexities, and advancements in manufacturing technologies. Governments and healthcare providers worldwide are emphasizing cost-effective drug alternatives, leading to a surge in generic drug production. The rising expiration of branded drug patents has further fueled the market, creating opportunities for contract manufacturers to support large-scale production.

Additionally, the globalization of pharmaceutical supply chains and the need for GMP-compliant facilities have prompted pharmaceutical companies to partner with CMOs specializing in regulatory compliance and quality assurance. The shift toward biosimilars and specialty generics has further increased demand for contract manufacturing expertise in complex formulations. Furthermore, the adoption of digital technologies, automation, and AI-driven manufacturing processes has enhanced production efficiency, reducing operational costs and improving drug quality. As the pharmaceutical landscape continues to evolve, contract manufacturing will remain a key enabler of scalability, cost-effectiveness, and global market expansion for generic drug producers.

SCOPE OF STUDY:

The report analyzes the Generic Pharmaceuticals Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (API, Drug Product); Drug (Branded Generics, Unbranded Generics); Route of Administration (Oral, Parenteral, Topical, Other Route of Administrations); Application (Oncology Application, Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • AbbVie Inc.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim
  • Catalent Pharma Solutions
  • CordenPharma
  • Dr. Reddy's Laboratories
  • Fareva
  • Hovione
  • Jubilant Life Sciences Limited
  • Laurus Labs Limited
  • Lonza Group
  • Lupin Limited
  • Piramal Pharma Solutions
  • Recipharm AB
  • Samsung Biologics
  • Siegfried Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Generic Pharmaceuticals Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surging Demand for Cost-Effective Drug Production Drives Growth in Generic Pharmaceuticals Contract Manufacturing
    • Expansion of Off-Patent Drug Pipelines Fuels Outsourcing of API and Formulation Manufacturing to CDMOs
    • Rising Price Pressures and Margin Compression in Generics Market Accelerate Move Toward Asset-Light Business Models
    • Growth of Emerging Markets with Local Generic Demand Strengthens Regional Contract Manufacturing Partnerships
    • Stringent Regulatory Compliance Requirements Encourage Pharma Companies to Partner with GMP-Certified CDMOs
    • OEM Focus on Scaling Up High-Volume Generic Production Enhances Investment in Dedicated Manufacturing Lines
    • Increasing Demand for Complex Generics, Including Injectables and Modified Release Formulations, Drives Specialized Outsourcing
    • Globalization of Pharma Supply Chains Supports Multi-Region Contract Manufacturing to Meet Local Compliance
    • Consolidation Among Big Pharma and Generics Players Boosts Strategic Partnerships with Global CDMOs
    • Outsourcing of Product Lifecycle Management and Reformulation Activities Strengthens End-to-End CDMO Value Propositions
    • Rising Investment in Oral Solids, Topicals, and Inhalation-Based Generic Products Expands Scope of Contract Manufacturing
    • OEMs Focus on Reducing Time-to-Market and Operational Risk by Outsourcing to Flexible CDMO Partners
    • Integration of Digital Manufacturing and Quality Control Systems Improves Process Transparency for Clients
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Generic Pharmaceuticals Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Drug Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Drug Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Drug Product by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Antidiabetic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Antidiabetic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Antidiabetic Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Anticoagulants Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Anticoagulants Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Anticoagulants Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Cardiovascular Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Respiratory Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Respiratory Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Respiratory Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Pain Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Pain Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Pain Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for HIV Antivirals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for HIV Antivirals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for HIV Antivirals Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Branded Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Branded Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Branded Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Unbranded Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Unbranded Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Unbranded Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: World 15-Year Perspective for Other Route of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 59: USA Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: USA 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Canada 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • JAPAN
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • CHINA
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 95: China Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • EUROPE
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • FRANCE
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 122: France Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: France 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 128: France Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: France 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • GERMANY
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Germany 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Germany 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Germany 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Italy 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Italy 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Italy 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Italy 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 158: UK Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: UK 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: UK 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 164: UK Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: UK 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 167: UK Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: UK 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Spain 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Spain 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Spain 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Spain 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Russia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Russia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Russia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Russia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Europe 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Europe 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Europe 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Asia-Pacific 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Australia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Australia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Australia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 230: Australia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Australia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Australia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • INDIA
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 233: India Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: India 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: India 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 239: India Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: India 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 242: India Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: India Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: India 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: South Korea 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: South Korea 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: South Korea 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 254: South Korea Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: South Korea Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: South Korea 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Rest of Asia-Pacific Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Latin America 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Latin America 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Latin America 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 281: Latin America Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Latin America Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Latin America 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Argentina 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Argentina 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Argentina 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 293: Argentina Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Argentina Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Argentina 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Brazil 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Brazil 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Brazil 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 305: Brazil Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Brazil Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Brazil 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Mexico 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Mexico 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Mexico 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 317: Mexico Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Mexico Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Mexico 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Rest of Latin America 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Rest of Latin America 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Rest of Latin America Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Rest of Latin America 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Middle East 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Middle East 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Middle East 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 344: Middle East Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Middle East Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Middle East 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Iran 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Iran 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Iran 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 356: Iran Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Iran Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Iran 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Israel 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Israel 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Israel 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 368: Israel Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Israel Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Israel 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Saudi Arabia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Saudi Arabia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Saudi Arabia Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Saudi Arabia 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: UAE 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: UAE 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: UAE 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 392: UAE Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: UAE Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: UAE 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Rest of Middle East 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Rest of Middle East 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Rest of Middle East Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Rest of Middle East 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030
  • AFRICA
    • Generic Pharmaceuticals Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Generic Pharmaceuticals Contract Manufacturing by Product - API and Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Africa 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Product - Percentage Breakdown of Value Sales for API and Drug Product for the Years 2015, 2025 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Generic Pharmaceuticals Contract Manufacturing by Application - Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Africa 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Immunology Application, Antidiabetic Application, Neurology Application, Anticoagulants Application, Cardiovascular Application, Respiratory Application, Pain Application, HIV Antivirals Application, Other Applications and Oncology Application for the Years 2015, 2025 & 2030
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Generic Pharmaceuticals Contract Manufacturing by Drug - Branded Generics and Unbranded Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 415: Africa 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Drug - Percentage Breakdown of Value Sales for Branded Generics and Unbranded Generics for the Years 2015, 2025 & 2030
    • TABLE 416: Africa Recent Past, Current & Future Analysis for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Africa Historic Review for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Oral, Parenteral, Topical and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 418: Africa 15-Year Perspective for Generic Pharmaceuticals Contract Manufacturing by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical and Other Route of Administrations for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제